Lv2
158 积分 2025-02-28 加入
A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial
2天前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
24天前
已完结
PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?
1个月前
已完结
Interleukin-10 in cancer immunotherapy: from bench to bedside
1个月前
已完结
Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions
7个月前
已完结
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
11个月前
已完结
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
11个月前
已完结
Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes
1年前
已完结
皖公网安备34019202002308
